VACBF (Nykode Therapeutics AS) Research & Development: $10.00 Mil (TTM As of Mar. 2026)


VACBF Nykode Therapeutics AS VACBF
28 GF Score
Price $0.32
GF Value $0.76
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Research & Development?

Nykode Therapeutics AS VACBF 28 Research & Development is $10.00 Mil as of Mar. 2026. GuruFocus rates VACBF with a GF Score™ of 28/100 and a GF Value™ of $0.76 (Possible Value Trap). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nykode Therapeutics AS's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $10.00 Mil.

Nykode Therapeutics AS  (OTCPK:VACBF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nykode Therapeutics AS Research & Development Related Terms

Nykode Therapeutics AS Research & Development Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Research & Development Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 16.30 26.77 29.36 14.73 6.98

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.00 3.20 3.80 0.00
VACBF
28GF Score
Nykode Therapeutics AS VACBF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $10.00 Mil mean?
Nykode Therapeutics AS (VACBF) has a Research & Development of $10.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Research & Development too high?
Nykode Therapeutics AS's current Research & Development is $10.00 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Research & Development compare to VRTX and REGN?
Nykode Therapeutics AS's Research & Development of $10.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Research & Development is $10.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.76, compared to a current price of $0.32 — trading 57.3% below its estimated fair value. The current Research & Development is $10.00 Mil. Nykode Therapeutics AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Research & Development is $10.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of $0.32 is trading 57.3% below its estimated GF Value™ of $0.76. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for VACBF:

  • Research & Development: $10.00 Mil
  • GF Value™: $0.76 vs. price of $0.32 (57.3% below fair value)
  • GF Score™: 28/100 with 2 warning signs

No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
28GF Score

Get the complete analysis for VACBF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price
$0.76
GF Value